Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Chemokine Receptor Antagonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Any agent that binds to and blocks any of the chemokine receptor subtypes. Chemokine receptors, members of the G-protein coupled receptor family, are predominantly expressed on the surface of leukocytes and play an important role in inflammation, infectious diseases, and cancer.
Heterocylic antiviral compounds
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 R6c and X1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treating diseases mediated by the CCR5 receptor.
Owner:ROCHE PALO ALTO LLC
Chemokine receptor antagonists and use thereof
InactiveUS8168783B2Prevention and therapyBiocideSenses disorderArterial Occlusive DiseasesMental nerve
Owner:ONO PHARMA CO LTD
Chemokine receptor antagonists and methods of use therefor
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and / or activation. The method comprises administering to a subject in need an effective amount of a compound represented by the following structural formula: ##STR1## and physiologically acceptable salts thereof.
Owner:KYOWA HAKKO KOGYO CO LTD +1
Heterocyclic antiviral compounds
InactiveUS20060014767A1Useful in treatmentBiocideOrganic active ingredientsChemokine Receptor AntagonistImmunodeficiency virus
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
Owner:ROCHE PALO ALTO LLC
Piperazinylpiperidine derivatives as chemokine receptor antagonists
ActiveUS20050261310A1Improve actionReduce releaseSilicon organic compoundsOrganic active ingredientsChemokine Receptor AntagonistHIV receptor
The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
Owner:INCYTE HLDG CORP
Methods for Treating or Preventing Cardiac and Neurological Disorders Using Chemokine Receptor Antagonists
InactiveUS20140057940A1Reduce the binding forceCardiac damageBiocideNervous disorderDiseaseChemokine Receptor Antagonist
Owner:MANKOWSKI JOSEPH L +1
Chemokine receptor antagonists and methods of use thereof
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and / or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof
Owner:MILLENNIUM PHARMA INC +1
Heterocyclic antiviral compounds
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
Owner:ROCHE PALO ALTO LLC
Chemokine receptor antagonists
Novel tetramic acid-type compounds isolated from a CCR-5 active complex produced by fermentation under controlled conditions of a biologically pure culture of the microorganism, Chaetomium globosum Kunze SCH 1705, ATCC 74489., pharmaceutical compositions containing the compounds and the use of the CCR-5 antagonist compounds and compositions to treat HIV-1 infections in humans are disclosed.
Owner:MERCK SHARP & DOHME CORP
Piperazinylpiperidine derivatives as chemokine receptor antagonists
ActiveUS7678798B2Reduce releaseOrganic active ingredientsSilicon organic compoundsChemokine Receptor AntagonistHIV receptor
Owner:INCYTE HLDG CORP
Screening for CXCR4 receptor antagonism polypeptides for treating breast carcinoma and its uses
InactiveCN101334411AAbility to block transferHigh specific binding activityPeptide/protein ingredientsBiological testingLymphatic SpreadBinding site
The invention provides a screening and modification method, a marker and an application of polypeptide drugs which are used in the treatment of CXCR4 receptor-mediated breast cancer. A human chemokine SDF-1 Alpha and the homology region of a human herpes virus 8 MIP-II are compared, thereby obtaining a binding site of vMIP-II and CXCR4 receptor and further obtaining a CXCR4 specific binding active peptide. With the role of specific binding CXCR4 and the blocking of the physiological binding of the SDF-1 Alpha and the CXCR4, the CXCR4 specific binding active peptide is a high-efficient and specific chemokine receptor antagonist. The chemotactic activity of wide type SDF-1 Alpha to breast cancer cells and the growth of the breast cancer cells can be inhibited, and the growth and the metastasis of the CXCR4-positive tumor cells are simultaneously inhibited, thereby having the dual-target effect. The invention further provides a marked polypeptide to be targetedly positioned in sentinel lymph node and metastatic site, thereby being used in the detection and the targeted radiotherapy of the metastatic status of the sentinel lymph node before and in the operation of the breast cancer.
Owner:BENGBU MEDICAL COLLEGE
Chemokine receptor antagonists as therapeutic agents
InactiveUS7465448B2Reduce immune toleranceReduced Tolerance RequirementsPeptide/protein ingredientsBiological material analysisTolerance inductionAbnormal tissue growth
The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and / or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.
Owner:GEORGIA HEALTH SCI UNIV RES INST
Methods of treating solid tumors with CCR2 antagonists
InactiveUS20190269664A1Reduce in quantityOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsCcr2 antagonistCD8
The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:
Owner:RGT UNIV OF CALIFORNIA +1
Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
InactiveCN101553493AStrong inhibitory activityLow affinityOrganic active ingredientsOrganic chemistryChemokine Receptor AntagonistCombinatorial chemistry
Owner:ASTRAZENECA AB
Chemokine receptor antagonists and methods of use thereof
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and / or activation. The method comprises administering to a subject in need an effective amount of a compound represented by structural formula (I) or physiologically acceptable salt thereof.
Owner:MILLENNIUM PHARMA INC +1
Diagnostic biomarker to predict women at risk for preterm delivery
InactiveUS20140051598A1Increased riskHigh and low expressionMicrobiological testing/measurementLibrary screeningChemokine Receptor AntagonistDiagnostic biomarker
The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and / or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood.
Owner:CEDARS SINAI MEDICAL CENT
Functionalized heterocycles as chemokine receptor modulators
The present invention is a novel series of functionalized heterocycles as chemokine receptor modulators of Formula (I) useful as modulators of chemokine receptor activity. The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the prepartion of the final products, pharmaceutical compositions containing the final products are also taught.
Owner:MILLENNIUM PHARMA INC
Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
![Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists](https://images-eureka.patsnap.com/patent_img/778d1ee0-ceb6-43c0-9899-cec43df33120/US07625905-20091201-C00001.png "Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists")
![Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists](https://images-eureka.patsnap.com/patent_img/778d1ee0-ceb6-43c0-9899-cec43df33120/US07625905-20091201-C00002.png "Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists")
![Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists](https://images-eureka.patsnap.com/patent_img/778d1ee0-ceb6-43c0-9899-cec43df33120/US07625905-20091201-C00003.png "Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists")
Owner:ROCHE PALO ALTO LLC
N-substituted heterocyclic amines as modulators of chemokine receptor activity
Owner:BRISTOL MYERS SQUIBB CO
Chemokine receptor antagonists and methods of use therefor
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and / or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
Owner:KYOWA HAKKO KIRIN CO LTD +1
Cell migration assay
InactiveUS20050186556A1Bioreactor/fermenter combinationsCompound screeningChemokine Receptor AntagonistCell Migration Assay
Owner:CHEMOCENTRYX INC
Piperazinylpiperidine derivatives as chemokine receptor antagonists
ActiveUS20090197887A1Improve actionReduce releaseBiocideAntipyreticChemokine Receptor AntagonistHIV receptor
The present invention relates to compounds of Formula I:wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
Owner:INCYTE HLDG CORP
Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
The present invention relates to a combination of (a) a chemokine receptor 1 (CCR1) antagonist and (b) a muscarinic antagonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treatment of airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases.
Owner:ASTRAZENECA AB
Chemokine receptor antagonists as therapeutic agents
InactiveUS20090041787A1Reduced Tolerance RequirementsReduce tumorgenicity in a subjectPeptide/protein ingredientsBiological material analysisTolerance inductionAbnormal tissue growth
The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and / or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.
Owner:MUNN DAVID H +2
Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
ActiveUS11446289B2Reduce tumor weightOrganic active ingredientsColon cancer vaccineChemokine Receptor AntagonistCancer therapy
The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
Owner:CHEMOCENTRYX INC
Antagonists of chemokine receptors
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Owner:CHEMOCENTRYX INC
Methods of treating solid tumors with ccr2 antagonists
PendingUS20210346361A1Reduce in quantityOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsChemokine Receptor AntagonistCcr2 antagonist
Owner:CHEMOCENTRYX INC +1
Methods of treating solid tumors with ccr2 antagonists
ActiveUS20190209573A1Reduce in quantityOrganic active ingredientsAntineoplastic agentsCcr2 antagonistChemokine Receptor Antagonist
The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I:
Owner:RGT UNIV OF CALIFORNIA +1
Solid forms of a chemokine receptor antagonist and methods of use thereof
The citrate salt of (S)-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol, which may be used in pharmaceutical applications, is disclosed. The crystalline Citrate Salt, including particular single crystal forms and combinations of the single crystalline forms, are also discussed. Mixtures for forming the crystalline salts are discussed. As well, methods of producing the Citrate Salt, and crystalline forms thereof, and using such Citrate Salt, and crystalline forms thereof, in treating diseases associated with aberrant leukocyte recruitment, activation, or recruitment and activation are also discussed.
Owner:MILLENNIUM PHARMA INC
Antagonists of chemokine receptors
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Owner:CHEMOCENTRYX INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com